This theory-building paper (2021) makes a case for using the therapeutic potential of psychedelics to treat neurodegenerative disorders such as Alzheimer’s disease. The ability of psychedelics to upregulate neurotrophic factors that promote neuronal survival and growth is discussed. Through their effects on structural and functional neuroplasticity and inflammation, psychedelics may prove useful in treating various aspects of neurodegenerative disorders.
“Psychedelics are increasingly being recognized for their potential to treat a wide range of brain disorders including depression, post-traumatic stress disorder (PTSD), and substance use disorder. Their broad therapeutic potential might result from an ability to rescue cortical atrophy common to many neuropsychiatric and neurodegenerative diseases by impacting neurotrophic factor gene expression, activating neuronal growth and survival mechanisms, and modulating the immune system. While the therapeutic potential of psychedelics has not yet been extended to neurodegenerative disorders, we provide evidence suggesting that approaches based on psychedelic science might prove useful for treating these diseases. The primary target of psychedelics, the 5-HT2A receptor, plays key roles in cortical neuron health and is dysregulated in Alzheimer’s disease. Moreover, evidence suggests that psychedelics and related compounds could prove useful for treating the behavioral and psychological symptoms of dementia (BPSD). While more research is needed to probe the effects of psychedelics in models of neurodegenerative diseases, the robust effects of these compounds on structural and functional neuroplasticity and inflammation clearly warrant further investigation.”
Authors: Hannah N. Saeger & David E. Olson
Find this paper
Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders
Open Access | Google Scholar | Backup | 🕊
Journal of Neurochemistry
November 24, 2021
Authors associated with this publication with profiles on BlossomDavid Olson
David Olson is the Chief Innovation Officer and Head of the Scientific Advisory Board at Delix Therapeutics. He is also an Associate Professor at UC Davis and his lab investigates the psychoplastogenic properties of psychedelic substances and other alkaloids, with respect to their ability to treat a wide variety of neuropsychiatric diseases, including depression, anxiety disorders, and addiction, by increasing neuroplasticity.